Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

Xiaoli Wang, Cing Siang Hu, Virginia Gillespie, Cecile Marie Krejsa, Ronald Hoffman

Blood (2021) 138 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2021-153071

Published: 2021

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Xiaoli Wang, MD PhD, Raajit K. Rampal, MD PhD, Cing Siang Hu, Noushin Farnoud, PhD, Christopher Famulare, MS, Minal A Patel, MPH, Erin McGovern, BA, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1677.

https://doi.org/10.1182/blood-2019-128836

Published: 2019

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, Raajit K. Rampal, MD PhD, Noushin Farnoud, Christopher Famulare, MS, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2018) 132 (Supplement 1): 101.

https://doi.org/10.1182/blood-2018-99-117348

Published: 2018

Journal Articles

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Xiaoli Wang, PhD, Cing Siang Hu, Raajit K. Rampal, MD PhD, Joseph Tripodi, Vesna Najfeld, PhD, Bruce Petersen, MD, John Mascarenhas, MD, Ronald Hoffman, MD

Blood (2017) 130 (Supplement 1): 2943.

https://doi.org/10.1182/blood.V130.Suppl_1.2943.2943

Published: 2017

Journal Articles

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Jiajing Qiu, Fei Huang, PhD, Ronald Hoffman, MD, Xiaoli Wang, PhD

Blood (2017) 130 (Supplement 1): 1654.

https://doi.org/10.1182/blood.V130.Suppl_1.1654.1654

Published: 2017

Journal Articles

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

Xiaoli Wang, Cing Siang Hu, Jiajing Qiu, Ronald Hoffman, MD

Blood (2016) 128 (22): 950.

https://doi.org/10.1182/blood.V128.22.950.950

Published: 2016

Journal Articles

A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells

Xiaoli Wang, David Haylock, Cing Siang Hu, Wioleta Kowalczyk, Tianbo Jiang, Jiajing Qiu, Goar Mosoyan, Wu He, Netonia Marshall, John Mascarenhas, Anna Tarasova, Joshua Brody, David Winkler, Ronald Hoffman

Blood (2016) 127 (26): 3398–3409.

https://doi.org/10.1182/blood-2015-10-674465

Published: 2016

Includes: Supplemental data

Journal Articles

A Thrombopoietin Antagonist Is Capable of Affecting Stem and Progenitor Cells of Patients with Myelofibrosis

Xiaoli Wang, David Haylock, Cing Siang Hu, Goar Mosoyan, Dave Winkler, Ronald Hoffman, MD

Blood (2014) 124 (21): 819.

https://doi.org/10.1182/blood.V124.21.819.819

Published: 2014

Journal Articles

Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells

Xiaoli Wang, Cing Siang Hu, Yan Li, Ronald Hoffman, MD

Blood (2014) 124 (21): 2145.

https://doi.org/10.1182/blood.V124.21.2145.2145

Published: 2014

Journal Articles

Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis

Xiaoli Wang, Cing Siang Hu, Yan Li, Jiajing Qiu, Morgan Lam, Kevin Eng, PhD, Ronald Hoffman, MD

Blood (2014) 124 (21): 1879.

https://doi.org/10.1182/blood.V124.21.1879.1879

Published: 2014

Journal Articles

JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

Xiaoli Wang, Fei Ye, Joseph Tripodi, Cing Siang Hu, Jiajing Qiu, Vesna Najfeld, Jesse Novak, Yan Li, Raajit Rampal, Ronald Hoffman

Blood (2014) 124 (19): 2987–2995.

https://doi.org/10.1182/blood-2014-02-558015

Published: 2014

Includes: Supplemental data

NARROW

Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells

Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients

A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells

A Thrombopoietin Antagonist Is Capable of Affecting Stem and Progenitor Cells of Patients with Myelofibrosis

Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells

Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis

JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only